指南与共识消化、代谢与肾脏急症重症综合管理与镇静镇痛

应用结构化共识框架识别药学教育中的基础药物知识

Identifying Foundational Drug Knowledge in Pharmacy Education Using a Structured Consensus Framework.
指南 / 共识 · J Am Coll Clin Pharm · 2026-01-01
一句话结论九人学术专家组与十名执业药师经Lawshe法共识,确定218种药学课程基础药物,急诊与重症药物在商业清单中存在系统性缺口。

本研究采用多阶段共识法(Lawshe法)确定药学课程基础药物清单。先由九人学术专家小组审阅整合治疗学课程中教授的1381种药物初始清单,再由十名代表不同临床环境的执业药师评估精炼清单,合并为19人共识小组。218种药物达成共识纳入:78种获一致共识(CVR=1.0),83种获近完全共识(CVR=0.895),57种达最低共识阈值(CVR=0.789)。与商业Top 300 Drugs清单比较,Jaccard相似指数0.408,重叠系数0.697;与商业清单的一致性随共识强度降低而下降,从一致共识药物的85%降至近完全共识的65%和最低阈值的56%,在阿片类镇痛药、静脉抗生素及急诊与重症药物方面存在系统性缺口。

要点

  • 19人共识小组用Lawshe法确定218种基础药物:78种CVR=1.0,83种CVR=0.895,57种CVR=0.789。
  • 共识最强的药物集中在心血管与血液、中枢神经系统和抗感染类别。
  • 与商业Top 300 Drugs清单的Jaccard相似指数0.408、重叠系数0.697。
  • 与商业清单一致性随共识强度下降:一致共识85%、近完全共识65%、最低阈值56%。
  • 商业清单在阿片类镇痛药、静脉抗生素及急诊与重症药物方面存在系统性缺口。

适用人群与场景

  • 药学课程教育者与课程设计者,用于确定需重点教授和评估的基础药物清单。
  • 研究纳入整合治疗学课程中教授的1381种药物初始清单,由学术专家小组和执业药师共同评估。

诊断标准与关键阈值

  • Lawshe法内容效度比(CVR)统计阈值:CVR=1.0为一致共识,CVR=0.895为近完全共识,CVR=0.789为最低共识阈值。

研究设计与关键结果

  • 多阶段共识研究:九人学术专家小组审阅1381种药物初始清单,十名执业药师评估精炼清单,合并为19人共识小组。
  • 218种药物达成共识纳入:78种CVR=1.0,83种CVR=0.895,57种CVR=0.789。
  • 共识最强的药物类别为心血管与血液、中枢神经系统和抗感染。
  • 与商业Top 300 Drugs清单比较:Jaccard相似指数0.408,重叠系数0.697。
  • 与商业清单一致性:一致共识药物85%,近完全共识65%,最低阈值56%。
  • 商业清单在阿片类镇痛药、静脉抗生素及急诊与重症药物方面存在系统性缺口。

证据类型、等级与局限

  • 证据类型:多阶段共识研究(Lawshe法)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为该研究提供了218种基础药物的验证共识框架和可复制方法,课程可据此开展聚焦的纵向评估,而非改变教学内容。
  • 商业Top 300 Drugs清单在阿片类镇痛药、静脉抗生素及急诊与重症药物方面存在系统性缺口,课程设计时需注意此差异。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Foundational drug knowledge is a central expectation for pharmacy practice-readiness, yet programs lack consensus-based guidance on which medications to prioritize or how intensively to assess them. Programs often use volume-derived drug lists as a pragmatic starting point, but such lists may not fully reflect the breadth of medications encountered across diverse practice settings. The purpose of the study is to identify a consensus-based foundational drug list reflective of the breadth of pharmacy practice.

METHODS: A multi-phase consensus study was conducted using the Lawshe method to establish content validity of essential drugs for a pharmacy curriculum. An initial inventory of 1381 drugs taught across an integrated therapeutics curriculum was reviewed by a nine-member academic expert panel, followed by evaluation of the refined list by 10 practicing pharmacists representing diverse clinical settings. Responses were merged to form a 19-member consensus panel. Drugs meeting statistical thresholds for essentiality were grouped by strength of expert agreement. The resulting list was compared with a commercially available Top 300 Drugs list using the Jaccard Similarity index.

RESULTS: A total of 218 drugs achieved consensus inclusion: 78 reached unanimous consensus with a content validity ratio (CVR) = 1.0, 83 reached near-complete consensus (CVR = 0.895), and 57 met the minimum consensus threshold (CVR = 0.789). Cardiovascular and hematology, central nervous system, and anti-infective classes were most heavily represented among drugs with the strongest consensus. Comparison with the commercial list yielded a Jaccard Similarity index of 0.408 and an overlap coefficient of 0.697. Concordance with the commercial list declined as consensus strength decreased, from 85% among unanimously endorsed drugs to 65% at near-complete consensus and 56% at the minimum threshold, with systematic gaps in opioid analgesics, intravenous antibiotics, and emergency and critical care medications.

CONCLUSION: This study provides a validated, consensus-derived framework of 218 foundational drugs and a replicable methodology that programs may use or adapt. The primary curricular application operates through focused, longitudinal assessment rather than changes to taught content.

来源:J Am Coll Clin Pharm,查看原文。版权归原作者所有。

参考来源

  1. Shultz B, Sawyer K, Schriever A, et al. Identifying Foundational Drug Knowledge in Pharmacy Education Using a Structured Consensus Framework. J Am Coll Clin Pharm. 2026. PMID: 42423234. doi:10.1002/jac5.70260

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。